| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Interferon-induced helicase C domain-containing protein 1 (EC 3.6.4.13) (Clinically amyopathic dermatomyositis autoantigen 140 kDa) (CADM-140 autoantigen) (Helicase with 2 CARD domains) (Helicard) (Interferon-induced with helicase C domain protein 1) (Melanoma differentiation-associated protein 5) (MDA-5) (Murabutide down-regulated protein) (RIG-I-like receptor 2) (RLR-2) (RNA helicase-DEAD box protein 116), IFIH1, MDA5 RH116 |
| Antigen | |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human MDA5 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a recombinant monoclonal antibody expressed in HEK293F cells. |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Primary AntibodyThis antibody targets IFIH1 and was raised against a recombinant protein immunogen.
Validated Applications
| Application | Recommended Dilution |
|---|---|
| ELISA | WB:1:500-1:5000 |
| Western Blot (WB) | WB:1:500-1:5000 |
Antibody Specifications
| Target | IFIH1 |
|---|---|
| Host | Rabbit |
| Clonality | Monoclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Antigen / Immunogen | A synthesized peptide derived from human MDA5 |
| Clone Number | 3D12 |
| Production | This product is a recombinant monoclonal antibody expressed in HEK293F cells. |
| Form | Liquid |
| Storage Buffer | PBS, 150mM NaCl, 50% Glycerol, 0.05% BSA, 0.02% Sodium Azide, pH 7.4. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Alternative Names
Interferon-induced helicase C domain-containing protein 1 (EC 3.6.4.13) (Clinically amyopathic dermatomyositis autoantigen 140 kDa) (CADM-140 autoantigen) (Helicase with 2 CARD domains) (Helicard) (Interferon-induced with helicase C domain protein 1) (Melanoma differentiation-associated protein 5) (MDA-5) (Murabutide down-regulated protein) (RIG-I-like receptor 2) (RLR-2) (RNA helicase-DEAD box protein 116), IFIH1, MDA5 RH116
Safety & Handling
| Target | IFIH1 |
| Host | Rabbit |
| Clonality | Monoclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse |
| Purification | Affinity Purification |
| Antigen/Immunogen | A synthesized peptide derived from human MDA5 |
| Clone Number | 3D12 |
| Production | This product is a recombinant monoclonal antibody expressed in HEK293F cells. |
| Form | Liquid |
| Storage Buffer | PBS, 150mM NaCl, 50% Glycerol, 0.05% BSA, 0.02% Sodium Azide, pH 7.4. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Dilutions are starting recommendations. Titration is advised for each system.
| Application | Recommended Dilution |
|---|---|
| ELISA | WB:1:500-1:5000 |
| Western Blot (WB) | WB:1:500-1:5000 |
Immunogen: A synthesized peptide derived from human MDA5
Antigen Species: Human
Alternative Names
Interferon-induced helicase C domain-containing protein 1 (EC 3.6.4.13) (Clinically amyopathic dermatomyositis autoantigen 140 kDa) (CADM-140 autoantigen) (Helicase with 2 CARD domains) (Helicard) (Interferon-induced with helicase C domain protein 1) (Melanoma differentiation-associated protein 5) (MDA-5) (Murabutide down-regulated protein) (RIG-I-like receptor 2) (RLR-2) (RNA helicase-DEAD box protein 116), IFIH1, MDA5 RH116
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
